219 related articles for article (PubMed ID: 25620011)
1. Noncoding oligonucleotides: the belle of the ball in gene therapy.
Shum KT; Rossi JJ
Adv Genet; 2015; 89():153-177. PubMed ID: 25620011
[TBL] [Abstract][Full Text] [Related]
2. Non-coding RNAs: Therapeutic Strategies and Delivery Systems.
Ling H
Adv Exp Med Biol; 2016; 937():229-37. PubMed ID: 27573903
[TBL] [Abstract][Full Text] [Related]
3. Liver as a target for oligonucleotide therapeutics.
Sehgal A; Vaishnaw A; Fitzgerald K
J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039
[TBL] [Abstract][Full Text] [Related]
4. [Therapeutic oligonucleotides: a review].
Wang X; Xian J; Chen G; Peng H
Sheng Wu Gong Cheng Xue Bao; 2018 May; 34(5):664-675. PubMed ID: 29893074
[TBL] [Abstract][Full Text] [Related]
5. Current RNA-based Therapeutics in Clinical Trials.
Zhou LY; Qin Z; Zhu YH; He ZY; Xu T
Curr Gene Ther; 2019; 19(3):172-196. PubMed ID: 31566126
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular RNA interference therapy: the broadening tool and target spectrum.
Poller W; Tank J; Skurk C; Gast M
Circ Res; 2013 Aug; 113(5):588-602. PubMed ID: 23948584
[TBL] [Abstract][Full Text] [Related]
7. Oligonucleotides for upregulating gene expression.
Khorkova O; Hsiao J; Wahlestedt C
Pharm Pat Anal; 2013 Mar; 2(2):215-29. PubMed ID: 24237027
[TBL] [Abstract][Full Text] [Related]
8. Nucleic acid-based techniques for post-transcriptional regulation of molecular targets.
Jarad G; Simske JS; Sedor JR; Schelling JR
Curr Opin Nephrol Hypertens; 2003 Jul; 12(4):415-21. PubMed ID: 12815338
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic nucleic acids: current clinical status.
Sridharan K; Gogtay NJ
Br J Clin Pharmacol; 2016 Sep; 82(3):659-72. PubMed ID: 27111518
[TBL] [Abstract][Full Text] [Related]
10. [Oligonucleotide therapeutics - an emerging novel class of compounds].
Wacheck V
Wien Med Wochenschr; 2006 Sep; 156(17-18):481-7. PubMed ID: 17041803
[TBL] [Abstract][Full Text] [Related]
11. The Clinical Potential of Oligonucleotide Therapeutics against Pancreatic Cancer.
Takakura K; Kawamura A; Torisu Y; Koido S; Yahagi N; Saruta M
Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31284594
[TBL] [Abstract][Full Text] [Related]
12. Targeting Functional Noncoding RNAs.
Crossley MP; Krude T
Methods Mol Biol; 2017; 1565():151-160. PubMed ID: 28364241
[TBL] [Abstract][Full Text] [Related]
13. The versatility of oligonucleotides as potential therapeutics.
Eckstein F
Expert Opin Biol Ther; 2007 Jul; 7(7):1021-34. PubMed ID: 17665991
[TBL] [Abstract][Full Text] [Related]
14. RNA Therapeutics: How Far Have We Gone?
Coutinho MF; Matos L; Santos JI; Alves S
Adv Exp Med Biol; 2019; 1157():133-177. PubMed ID: 31342441
[TBL] [Abstract][Full Text] [Related]
15. RNA interference in mammalian cell systems.
Lochmatter D; Mullis PE
Horm Res Paediatr; 2011; 75(1):63-9. PubMed ID: 21252559
[TBL] [Abstract][Full Text] [Related]
16. Aptamers against extracellular targets for in vivo applications.
Pestourie C; Tavitian B; Duconge F
Biochimie; 2005; 87(9-10):921-30. PubMed ID: 15963620
[TBL] [Abstract][Full Text] [Related]
17. Application of decoy oligonucleotides as novel therapeutic strategy: a contemporary overview.
Ahmad MZ; Akhter S; Mallik N; Anwar M; Tabassum W; Ahmad FJ
Curr Drug Discov Technol; 2013 Mar; 10(1):71-84. PubMed ID: 22780867
[TBL] [Abstract][Full Text] [Related]
18. Clinical applications of aptamers and nucleic acid therapeutics in haematological malignancies.
Shigdar S; Ward AC; De A; Yang CJ; Wei M; Duan W
Br J Haematol; 2011 Oct; 155(1):3-13. PubMed ID: 21810089
[TBL] [Abstract][Full Text] [Related]
19. Nucleic acid aptamers as tools and drugs: recent developments.
Rimmele M
Chembiochem; 2003 Oct; 4(10):963-71. PubMed ID: 14523912
[TBL] [Abstract][Full Text] [Related]
20. Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease.
Sardone V; Zhou H; Muntoni F; Ferlini A; Falzarano MS
Molecules; 2017 Apr; 22(4):. PubMed ID: 28379182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
